Reporting of determinants of health inequities and participant characteristics in randomized controlled trials of systemic lupus erythematosus in Canada: A scoping review

被引:0
|
作者
Thomas, Megan [1 ,2 ,3 ]
Verma, Vanay [1 ]
Gheshlaghi, Niloofar [1 ]
Esdaile, John [3 ]
Avina-Zubieta, Antonio [3 ]
Barnabe, Cheryl [3 ,4 ]
Harrison, Mark [1 ,2 ,5 ]
De Vera, Mary A. [1 ,2 ,3 ,5 ,6 ]
机构
[1] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada
[2] Collaborat Outcomes Res & Evaluat, Vancouver, BC, Canada
[3] Arthrit Res Canada, Vancouver, BC, Canada
[4] Univ Calgary, Dept Med, Calgary, AB, Canada
[5] Ctr Adv Hlth Outcomes, Vancouver, BC, Canada
[6] Univ British Columbia, Fac Pharmaceut Sci, 2405 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada
基金
加拿大健康研究院;
关键词
Equity; diversity; and inclusion; systemic lupus erythematosus; scoping review; DISPARITIES; ARTHRITIS; CARE; POPULATION; PREVALENCE; OUTCOMES;
D O I
10.1177/09612033241233032
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To report participant characteristics relevant to identifying health inequities in systemic lupus erythematosus (SLE) randomized controlled trials conducted in Canada.Methods We conducted a scoping review by searching MEDLINE (Ovid) and Embase (1990 to June 2023), and CENTRAL (inception to June 2023). Eligible studies: used an RCT design; evaluated interventions (pharmacologic and non-pharmacologic) among SLE patients aged >= 18 years; and were conducted in Canada. Data extraction was guided by the Campbell and Cochrane Equity Methods Group's PROGRESS-Plus framework on 11 factors leading to health inequities (Place of residence; Race, culture, ethnicity, and language; Occupation; Gender and sex; Religion; Education; Socioeconomic status; Social capital; Plus: Personal characteristics associated with discrimination; Features of relationships; and Time-dependent relationships).Results Of 1901 unique records, 6 met the inclusion criteria. Sex and age were the only PROGRESS factors that were reported in all studies. The majority of participants were female (84.4% to 100%), and mean ages of participants ranged from 42 to 52.3 years. Place of residence, race, education, and social capital were reported in three studies. Socioeconomic status was reported in two studies, and occupation was reported in one study. Religion, features of relationships, and time-dependent relationships were not reported in any included studies.Conclusion Limited reporting of determinants of health inequities in RCTs for SLE in Canada suggests the need for reporting standards to support equity, diversity, and inclusion practices in research.
引用
收藏
页码:462 / 469
页数:8
相关论文
共 50 条
  • [31] Commentary on "The Characteristics and Ethics of Sham Surgeries" A Systemic Review of Randomized Controlled Trials
    Angelos, Peter
    Rogers, Selwyn O.
    ANNALS OF SURGERY, 2023, 278 (02) : 159 - 160
  • [32] Qualitative studies conducted alongside randomized controlled trials in oncology: A scoping review of use and rigour of reporting
    Thiessen, M.
    Harris, D.
    Pinches, A.
    Vaska, M.
    Moules, N.
    Bouchal, S. Raffin
    Sinclair, S.
    INTERNATIONAL JOURNAL OF NURSING STUDIES, 2022, 128
  • [33] Inclusion of older adults and reporting of consent processes in randomized controlled trials in the emergency department: A scoping review
    Southerland, Lauren T.
    Benson, Katherine K.
    Schoeffler, Austin J.
    Lashutka, Margaret A.
    Borson, Soo
    Bischof, Jason J.
    JOURNAL OF THE AMERICAN COLLEGE OF EMERGENCY PHYSICIANS OPEN, 2022, 3 (04)
  • [34] Assessing the steroid-sparing effect of biological agents in randomized controlled trials for lupus: a scoping review
    Sciascia, Savino
    Foddai, Silvia Grazietta
    Arbrile, Marta
    Radin, Massimo
    Cecchi, Irene
    Barinotti, Alice
    Fenoglio, Roberta
    Roccatello, Dario
    IMMUNOLOGIC RESEARCH, 2024, 72 (04) : 538 - 553
  • [35] Efficacy and safety of statins in the prevention of atherosclerosis in patients with systemic lupus erythematosus - A meta-analysis of randomized controlled trials
    Ye, Yicong
    Zhao, Xiliang
    Xie, Hongzhi
    Tian, Zhuang
    Zhang, Shuyang
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 167 (01) : 301 - 303
  • [36] Efficacy and Safety of Vitamin D Supplementation in Patients With Systemic Lupus Erythematosus: A Meta-analysis of Randomized Controlled Trials
    Zheng, Ronghao
    Gonzalez, Alex
    Yue, Jing
    Wu, Xiaolin
    Qiu, Ming
    Gui, Lin
    Zhu, Songbai
    Huang, Li
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2019, 358 (02): : 104 - 114
  • [37] Randomized controlled trials in systemic lupus erythematosus: what has been done and what do we need to do?
    Schiffenbauer, J
    Simon, LS
    LUPUS, 2004, 13 (05) : 398 - 405
  • [38] A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus
    Werth, V. P.
    Merrill, J. T.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (05) : 964 - 965
  • [39] Digital Health Interventions for Adult Patients With Cancer Evaluated in Randomized Controlled Trials: Scoping Review
    Lee, Kyunghwa
    Kim, Sanghee
    Kim, Soo Hyun
    Yoo, Sung-Hee
    Sung, Ji Hyun
    Oh, Eui Geum
    Kim, Nawon
    Lee, Jiyeon
    JOURNAL OF MEDICAL INTERNET RESEARCH, 2023, 25 (01)
  • [40] REPORTING CHARACTERISTICS OF RANDOMIZED CONTROLLED TRIALS OF ENDOVASCULAR THERAPY FOR PERIPHERAL ARTERY DISEASE: A SYSTEMATIC REVIEW
    Williams, A. O.
    McGovern, A.
    Jacobsen, C.
    Hargens, L.
    Duval, S.
    Jaff, M. R.
    Long, C.
    VALUE IN HEALTH, 2024, 27 (06) : S288 - S289